The speculation is building this week that Pfizer will either attempt another megadeal with GlaxoSmithKline or another run on AstraZeneca. Either would cut Pfizer's tax rate and give it some products to salve its various ills, lackluster stock price and poor performing portfolio. But the new thinking, like in the last 24 hours, is that smaller deals, perhaps a buyout of Shire or even Perrigo, or both, are better bets.
Hospira is voluntarily recalling 181,704 bags of magnesium sulfate in 5% dextrose injections because labels on the immediate container may have barcodes indicating that it is instead the blood thinner heparin.
Pfizer needs to make a deal--or several. It's obviously amenable to another megamerger, given that it tried to snap up AstraZeneca for more than $100 billion last year. So why not GlaxoSmithKline?
The latest market chatter is that Pfizer, rebuffed in its quest to acquire AstraZeneca last year, is taking a hard look at GlaxoSmithKline, and one analyst says it might be a good idea.
India's policy regarding intellectual property protection has bounced back once again to deny an MNC patent challenged by a local drugmaker. This one was filed by the local unit of Fresenius Kabi Oncology against a Pfizer patent.
Pfizer and Bristol-Myers Squibb's new-age anticoagulant, Eliquis, has been ramping up after a slow start. But Johnson & Johnson, maker of market leader Xarelto, need not worry, thanks to that med's wide base of indications and hefty clinical trials program.
Johnson & Johnson and Bayer are wont to brag about their achievements with Xarelto, one of the new generation of anticoagulant meds. Rightfully so: Though second to that market by many months, the companies grabbed market share from their old standby rival warfarin and their head-to-head competition Pradaxa, too.
The curtain is up on the first act of the annual cancer drug lollapalooza at ASCO. The first round of abstracts spotlights a series of early winners--including Roche--and at least one big loser: Puma Biotechnology.
In the department of employee lawsuits, Pfizer is the latest drugmaker in the hot seat. But the seat is hotter for the visually impaired sales rep who sued because the company wouldn't provide a driver to ferry her to doctors' offices.
When it comes to Big Pharma's reputation, "average" says it all. That's the story from the research firm Reputation Institute, which perennially puts major drugmakers right smack in the middle of its scorecard. In other words, pharma is a C student.